BASEL, Switzerland, September 16, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a biopharmaceutical company dedicated to improving healthcare for women and men through focused science, the power of medicine and advancement of change, announced today the support of 7 new employees under the Myovant Incentive Plan for 2020. On September 15, 2022, the Company announced capital reserve approval. The awards are presented to employees who join Myovant in accordance with Rule 303A.08 of the New York Stock Exchange Rules.
New employees received Restricted Use Shares (RSU) to purchase a total of 37,700 Myovant common shares. Rights to one-fourth of the shares underlying each employee's PSU vest one year from the date of grant, and the remaining common shares vest in twelve equal quarterly installments on any occasion during each employee's expected service life. . Myowant this weekend. RSU is subject to the terms of the 2020 Incentive Plan and applicable RSU agreements.
About Mayovant Sciences Mayovant Sciences is committed to reshaping healthcare for women and men through empowered science, advancing medicine and driving change. Founded in 2016, Myovant has successfully completed five Phase 3 clinical trials in oncology and women's health, including the U.S. Food and Drug Administration (FDA) in men with advanced prostate cancer, women with heavy menstrual bleeding associated with uterine fibroids, and moderate to moderate severe pain associated with endometriosis Premenopausal women using Myovant also received regulatory approval from the European Commission (EC) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and men with advanced hormone-sensitive prostate cancer. Another new drug application for Myovant is pending with the US FDA for Prescribing Information (USPI) with safety and efficacy data from the randomized phase 3 withdrawal study LIBERTY MYFEMBREE in premenopausal women with heavy menstrual bleeding for up to two years with uterine bleeding. fibroids. Myovant is conducting a phase 3 study to evaluate contraception in women with uterine fibroids or endometriosis. Myovant is developing MVT-602, an investigational kisspeptin-1 receptor oligopeptide agonist that has completed a Phase 2a study in female infertility as an add-on treatment for infertility. Sumitomo Pharmaceutical Co., Ltd., a subsidiary of Sumitovant Biopharma, Ltd., is the controlling shareholder of Myovant. Visit www.myovant.com for more information. Follow @Myovant on Twitter and LinkedIn.
Contact Myovant Sciences Investor contact: Uneek Mehra Head of Finance & Business, Myovant Sciences, Inc.investors@myovant.com
Media Contact: Noel Claude Dugan, Vice President of Corporate Communications, Myovant Sciences, Inc.media@myovant.com
